DAFTAR PUSTAKA

Adukauskiene, Dalia et al. 2016. “Clinical Relevance of High Sensitivity C-Reactive Protein in Cardiology.” *Medicina (Lithuania)* 2016: 52(1): 1–10. DOI: 10.1016/j.medici.2015.12.001.

Ahmad, Mahmood, Muhammad Usman, and Muhammad Sohail. 2012. “Pharmacokinetic Interactions of Rosuvastatin : A Review.” *J Pharmacy Alternat Medicine* 2012: 2(January): 1–7.

Amanda H. Corbett, William K.Dana. 2014. “Drug Information Handbook_23rd.Ed_2014-2015.Pdf.” : 2666.

Ansar, Waliza, and Shyamasree Ghosh. 2013. “C-Reactive Protein and the Biology of Disease.” *Immunologic Research*.2013: 56(1): 131–142. DOI: 10.1008/s12026-013-8384.0.

Arévalo-Lorido, José Carlos. 2016. “Clinical Relevance for Lowering C-Reactive Protein with Statins.” *Annals of Medicine*. 2016 : 48(7): 516–524. DOI:10.1080/07853890.2016.1197413.

Arnaud, Claire et al. 2005. “Statins Reduce Interleukin-6-Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins.” *Arteriosclerosis, Thrombosis, and Vascular Biology*. 20015: 25(6): 1231–1236.DOI: 10.1161/01.ATV.0000163840.63685.oc.

barbara g.wells, Joseph T.DiPiro, Terry L.Schwinghammer. 2012. 1 Laser Focus World *Pharmacotherapy Handbook*.

Bharath Kumar, A., M. S. Umashankar, K. S. Lakshmi, and V. Sriram. 2019. “Pharmacodynamic and Pharmacokinetic Overview on Statins in the Management of Hyperlipidemic Complications in Clinical Practice.” *Drug Invention Today*. 2019: 11(5): 1063–1070.

Cardoso, Filipe S. et al. 2015. “C-Reactive Protein at 24 Hours after Hospital Admission May Have Relevant Prognostic Accuracy in Acute Pancreatitis: A Retrospective Cohort Study.” *GE Portuguese Journal of Gastroenterology* 22(5): 198–203.DOI:10.1016/j.jpge.2015.03.002.

Chahyanto, Bibi Ahmad, Sri Anna Marliyati, and Wiwin et al Winarsih. 2017. “Efek Diet Tinggi Kolesterol Terhadap Peningkatan Kolesterol Darah, Gambaran Histopatologi Hati, Dan Bobot Badan Kelinci New Zealand White Jantan.” *Jurnal Sain Veteriner*. 2016: 34(1): 50–59.

Chandrashekara. 2014. “C - Reactive Protein: An Inflammatory Marker with

Specific Role in Physiology, Pathology, and Diagnosis." *Internet Journal of Rheumatology and Clinical Immunology*.2014: 2(S1): 1–23. DOI: 10.15305/ijrci/v2iS1/117

Chinetti-Gbaguidi, Giulia, Jean Charles Fruchart, and Bart Staels. 2005. "Pleiotropic Effects of Fibrates." *Current Atherosclerosis Reports*.2005: 7(5): 396–401. DOI: 10.1007/s11883-005-0053-x

David, A. J. et al. 2009. "LDH and G-6PDH Activities in the Ovaries of Adult Female Wistar Rats Following the Administration of Aqueous Extracts of Neem Azadirachta Indica Leaves." *African Journal of Biotechnology.*2009: 8(7): 1310–1313.

Duan, Yehui et al. 2018. "Inflammatory Links Between High Fat Diets and Diseases." *Frontiers in Immunology*. 2018: 13(9): 1–10.DOI: 10.3389/timmu.2018.02649.

Edelman, Alison B., Ganesh Cherala, and Frank Z. Stanczyk. 2010. "Metabolism and Pharmacokinetics of Contraceptive Steroids in Obese Women: A Review." *Contraception*. 2010: 82(4): 314–323. DOI: 10.1016/j.contraception.2010.04.016.

Gupta, Sunanda. 2006. "Obesity and Female Hormones." *The Obstetrician & Gynaecologist* 2006; 8(1):26-31.DOI:10.1576/toag.8.1.026.27205.

Heryani, Reni. 2016. "Pengaruh Ekstrak Buah Naga Merah Terhadap Profil Lipid Darah Tikus Putih Hiperlipidemia." *Jurnal Iptek Terapan*. 2016; 10(1): 8-17. DOI: 10.22216/jit.2016.v10i1.372.

Humaish, Haider Hafudh. 2020. "Evaluation the Relationship between Oral Contraceptives Containing Drospirenone with Dyslipidemia and Risk of Cardiovascular Diseases among Women in Al-Kut City." *Indian Journal of Forensic Medicine and Toxicology*. 2020;14(4): 1920–1926. DOI: 10.37506/ijfmt.v14i4.11827.

Kartika, Yusri, and Sudarto Ronoatmodjo. 2019. "Penggunaan Kontrasepsi Hormonal Dan Obesitas Pada Wanita Usia Subur Di Indonesia: Analisis Data Ifls 5 Tahun 2014." *Jurnal Kesehatan Reproduksi*. 2019; 10(2): 101–110. DOI: 10.22435/KESPRO.v10i2.2412.

Khalil, Ayman, Hasan Omran, and Fatima Alsheikh. 2018. "Balance of Pro- and Anti-Inflammatory Cytokines in Livers of High Fat Diet Rats Exposed to Fractionated Gamma Irradiation." *BMC Research Notes*.2011; 11(1): 1–6. DOI: 10.1186/s13104-018-3851-2.

Kraetschmer, K. 2018. “Pharmacology Research Exploring Contraception.” *Journal Pharmacol Res*. 2018; 2(1): 5–13.

Kusuma, Anjar Mahardian, Yupin Asarina, Yeni Indah Rahmawati, and Susanti Susanti. 2017. “Efek Ekstrak Bawang Dayak (Eleutherine Palmifolia (L.)Merr) Dan Ubi Ungu (Ipomoea Batatas L) Terhadap Penurunan Kadar Kolesterol Dan Trigliserida Darah Pada Tikus Jantan.” *Jurnal Kefarmasian Indonesia* 6(2): 108–116.

Leksana, Ery. 2013. “Systemic Inflammatory Response Syndrome.” *Robinson’s Current Therapy in Equine Medicine: Seventh Edition* 40(1): 7–11.

Ling. 2013. “A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.” *Cardiology Research*. 2013; 4(2): 47–55. DOI: 10.4021/cr270w.

Lingga, i made gede dwi. 2017. “Uji Diagnostik C-Reactive Protein , Leukosit, Nilai Total Neutrofil Dan Suhu Pada Anak Demam Dengan Penyebab Yang Tidak Diketahui.” *Sari Pediatri* 2(1): 412–419.

Lokesh, Kavyashree, and K Jayanthi. 2015. “Lactate Dehydrogenase : An Enzymatic Biomarker in Oral Health and Disease.” *international journal of contemporary dental and medical reviews*. 2015; 3–5. DOI:10.15713/ins.ijcdmr.88.

Lopez LM. Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor. *J Am Pharm Assoc*. 2012;45(4):503-513.

Luan, Ying Yi, and Yong Ming Yao. 2018. “The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases.” *Frontiers in Immunology*.2018; 9: 1–8. DOI: 10.3389.timmu.2018.01302.

Luvai, Ahai, Wycliffe Mbagaya, Alistair S. Hall, and Julian H. Barth. 2012. “Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease.” *Clinical Medicine Insights: Cardiology*.2012; 6: 17–33.DOI: 10.4137/CMC.S4324.

Meredith, Kent G. et al. 2007. “Comparison of Effects of High (80 Mg) Versus Low (20 Mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing.” *American Journal of Cardiology*. 2007; 99(2): 149–153.DOI: 10.1016/j.amjcard.2006.07.079.

Nadipelly, Jagan. 2017. “Molecular Mechanisms Involved in Inflammatory Cascade: A Review.” *Texila International Journal of Basic Medical Sciences*. 2017; 2(1): 1–12.DOI: 10.21522/TIJBMS.2016.02.01.Art001

Nair, AnroopB, and Shery Jacob. 2016. “A Simple Practice Guide for Dose Conversion between Animals and Human.” *Journal of Basic and Clinical Pharmacy*.2017; 7(2): 27.DOI: 10.4103/0976-0105.177703.

Narulita, Erlia, and Jekti Prihatin. 2017. “Kontrasepsi Hormonal Jenis, Fisiologi Dan Pengaruhnya Bagi Rahim.” *UPT Penerbitan Universitas Jember*: 1–69.

Naz, Falaq et al. 2016. “Effect of Oral Contraceptive Pills on the Blood Serum Enzymes and DNA Damage in Lymphocytes Among Users.” *Indian Journal of Clinical Biochemistry*. 2016; 31(3): 294–301. DOI: 10.1007/s12291-015-0533-x.

Neda Shakour, Massimiliano Ruscica, Farzin Hadizadeh. 2020. “Statin and C-Reactive Protein: In Sillico Evidence on Direct Interaction.” *Archives of Medical Science* 16(6): 1461–1463. DOI: 10.5114/aoms.2020.100304

Norvegicus, Rattus, and Novita Sari. 2021. “AKTIFITAS FISIK INTENSITAS BERAT PADA TIKUS PUTIH.” *jurnal ilmiah ilmu keolahragaan* 5(April): 61–69.

Novalia, Sari dan. 2015. “Kontrasepsi Hormonal Suntik Depo Medroxyprogesterone Acetate (DMPA) Sebagai Salah Satu Penyebab Kenaikan Berat Badan.” *Jurnal Majority* 4(7): 67–72.

Novara, Tendi, Ika Murti Harini, and Sutrisno Sutrisno. 2019. “Perbedaan Kadar Laktat Dehidrogenase (LDH) Pada Berbagai Derajat Keparahan Preeklampsia.” *Jurnal Kedokteran Brawijaya* 30(4): 272.

Poggiali, Erika et al. 2020. “Lactate Dehydrogenase and C-Reactive Protein as Predictors of Respiratory Failure in CoVID-19 Patients.” *Clinica Chimica Acta*. 2020; 509(June): 135–138. DOI: 10.1016/J.oca.2020.06.012

Prima, K. 2015. “Hubungan Antara Kadar Lactat Dehidrogenase (Ldh) Serum Dan Asam Urat Pada Penderita Leukemia Berdasarkan Gambaran ….” *Jurnal Medika Malahayati* 2(2): 59–64.

Puspitadewi, Irene Nucifera, Ani Margawati, and Hartanti Sandi Wijayanti. 2018. “Pengaruh Pemberian Sari Ubi Ungu (Ipomea Batatas L.) Terhadap KadarHigh Sensitivity C-Reactive Protein(Hs-CRP) Pada Tikus Sprague Dawley Dengan Pakan Tinggi Lemak.” *Journal of Nutrition College* 7(4):

155.

Rahman, Safriani. 2015. “Uji Efek Hipolipidemik Ekstrak Etanol Kayu Secang (Caesalpinia Sappan L) Terhadap Tikus Wistar (Rattus Norvegicus) Jantan.” *As-Syifaa* 07(02): 103–113.

Rahmawati, Ana. 2014. “Mekanisme Terjadinya Inflamasi Dan Stres Oksidatif Pada Obesitas.” *Mediators of Inflammation* 5(1): 1–8.

Van Rooijen, Marianne et al. 2006. “Treatment with Combined Oral Contraceptives Induces a Rise in Serum C-Reactive Protein in the Absence of a General Inflammatory Response.” *Journal of Thrombosis and Haemostasis* 4(1): 77–82.

Sahebkar, Amirhossein, Renato Giua, and Claudio Pedone. 2016. “Impact of Statin Therapy on Plasma Leptin Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.” *British Journal of Clinical Pharmacology*.2016; 82(6): 1674–1684. DOI: 10.1111/bcp.13086

Santos, Alan Carlos Nery dos et al. 2016. “C-Reactive Protein in Oral Contraceptive Users: Related Factors and Cardiovascular Risk.” *International Journal of Cardiovascular Sciences* 29(4): 320–325.

Shrestha Manisha, Anand Kumar. 2018. “Systemic Inflammatory Response Syndrome: The Current Status.” *Journal of Universal College of Medical Sciences* 06(01): 56–61.

Shrivastava, Amit Kumar, Harsh Vardhan Singh, Arun Raizada, and Sanjeev Kumar Singh. 2015. “C-Reactive Protein, Inflammation and Coronary Heart Disease.” *Egyptian Heart Journal*. 2015; 67(2): 89–97. DOI: 10.1016/j.ehj.2014.11.005.

Shufelt, Chrisandra L., and C. Noel Bairey Merz. 2009. “Contraceptive Hormone Use and Cardiovascular Disease.” *Journal of the American College of Cardiology*. 2009; 53(3): 221–231. DOI: 10.1016/j.jacc.2008.09.042.

Shuhaili Anuar Meor, Intan Nureslyna Samsudin. 2017. “Effects of Different Types of Statin on Lipid Profile : A Perspective on Asians.” *international endocrinol metab*. 2017: 15(2): 1–12. DOI: 10.5812/ijrm.43319

Škop, V. et al. 2016. “Hepatotoxic Effects of Fenofibrate in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein.” *Physiological Research*. 2016; 65(6): 891–899. DOI: 10.33549/physiolres.933304.

Sproston, Nicola R., and Jason J. Ashworth. 2018. “Role of C-Reactive Protein at Sites of Inflammation and Infection.” *Frontiers in Immunology* 9(APR): 1–11. DOI: 10.3389/fimmu.2018.00754.

Sriwahyuni, Efi, and Chatarina Umbul Wahyuni. 2012. “Hubungan Antara Jenis Dan Lama Pemakaian Alat Kontrasepsi Hormonal Dengan Peningkatan Berat Badan Akseptor.” *The Indonesian Journal of Public Health* 8(3): 112–116.

Sugga, G. S., M. U. Khan, and R. Khanam. 2012. “Protective Role of Fibrates in Cardiac Ischemia/Reperfusion.” *Journal of Advanced Pharmaceutical Technology and Research*. 2012; 3(3): 188–192. DOI: 10.4103/2231-4040.101016.

Torzewski, Michael, Ahmed Bilal Waqar, and Jianglin Fan. 2014. “Animal Models of C-Reactive Protein.” *Mediators of Inflammation*. 2014 2014(April): 1-7. DOI: 10.1155/2014/683598.

Tsimihodimos, Vasilis et al. 2005. “Fenofibrate: Metabolic and Pleiotropic Effects.” *Current Vascular Pharmacology*. 2005; 3(1): 87–98. DOI: 10.2174/1570161052773942.

Valvona, Cara J., Helen L. Fillmore, Peter B. Nunn, and Geoffrey J. Pilkington. 2016. “The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor.” *Brain Pathology*. 2016; 26(1): 3–17. DOI: 10.1111/bpa.12299.

Vlase, Laurian, Adina Popa, Dana Muntean, and Sorin E. Leucuta. 2010. “Pharmacokinetics and Comparative Bioavailability of Two Fenofibrate Capsule Formulations in Healthy Volunteers.” *Arzneimittel-Forschung/Drug Research.*2010; 60(9): 560–563. DOI: 10.1055/s-0031-1296325

Wang, Ling, Rong Lin, Langtao Guo, and Meiman Hong. 2018. “Rosuvastatin Relieves Myocardial Ischemia/Reperfusion Injury by Upregulating PPAR-Gamma And UCP2.” *Molecular Medicine Reports*. 2018;18(1):789-798. DOI: 10.3892/mmr.2018.9062.

Ward, Natalie C., Gerald F. Watts, and Robert H. Eckel. 2019. “Statin Toxicity: Mechanistic Insights and Clinical Implications.” *Circulation Research*. 2019; 124(2): 328–350. DOI: 10.1161/CIRCRESAHA.118.312782.

Wiggins, Barbara S. et al. 2016. “Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from

the American Heart Association." *Circulation*. 2016; 134(21): e468–e495. DOI: 10.1161/CIR.0000000000000456.

Wu, Li Wei et al. 2016. "Examining the Association between Serum Lactic Dehydrogenase and All-Cause Mortality in Patients with Metabolic Syndrome: A Retrospective Observational Study." *BMJ Open. 2016;* 6(5): 1-7. DOI: 10.1136/bmjopen-2016-01118.

LAMPIRAN

Lampiran 1. Skema Penelitian



Lampiran 2. Tabel Kadar Protein C-Reaktif dan Laktat Dehidrogenase

Tabel 5. Hasil Uji Kadar Protein C-Reaktif pada tikus Betina (Rattus norvergicus) setelah pemberian pil kontrasepsi (Andalan®), pakan Diet tinggi Lemak (kuning telur), dan NaCMC.

Perlakuan	Rerata±SD			P-Value (*paired sample t-test)*	P-value (one way ANOVA)
	Hari 0	Hari 30	Hari 60		
Pil kontrasepsi	2,36±0,18	2,55±0,25	2,72±0,16	0,350 [a] 0,05 [b]	
Pakan Lemak	221±0,16	2,52±0,14	2,66±0,23	0,09 [a] 0,06 [b]	0,756[c] 0,089[d]
Pil kontrasepsi + Pakan Lemak+ NaCMC	2,20±0,10	2,54±0,41	2,20±0,36	0,121 [a] 0,984 [b]	

Keterangan:
[a] Uji *paired sample t-test kadar Protein C-Reaktif* hari 0-30
[b] Uji *paired sample t-test kadar Protein C-Reaktif* hari 0-60
[c] Uji one way ANOVA persentase perubahan *kadar Protein C-Reaktif* ANOVA hari ke-0-30
[d] Uji one way ANOVA persentase perubahan *kadar Protein C-Reaktif* ANOVA hari ke-0-60

Tabel 6. Hasil Uji Kadar Laktat dihidrogenase pada tikus Betina (Rattus norvergicus) setelah pemberian pil kontrasepsi (Andalan®), pakan Diet tinggi Lemak (kuning telur), dan NaCMC

Perlakuan	Rerata±SD			P-Value (*paired sample t-test)*	P-value (one way ANOVA)
	Hari 0	Hari 30	Hari 60		
Pil kontrasepsi	472,7±219,2	674,1±455,5	330,5±189,2	0,419 [a] 0,395 [b]	
Pakan Lemak	545,5±277,7	1514,4±1662,7	4274,8±531,6	0,225 [a] 0,000 [b]	0,253 [c] 0,005 [d]
Pil kontrasepsi + Pakan Lemak+ NaCMC	640,7±181,8	908,5±308,7	952,4±236,3	0,099 [a] 0,152 [b]	

Keterangan:
[a] Uji *paired sample t-test kadar laktat dehidrogenase* hari 0-30
[b] Uji *paired sample t-test kadar laktat dehidrogenase* hari 0-60
[c] Uji one way ANOVA persentase perubahan *kadar laktat dehidrogenase* ANOVA hari ke-0-30
[d] Uji one way ANOVA persentase perubahan *kadar laktat dehidrogenase* ANOVA hari ke-0-60

Lampiran 3. Perhitungan dosis

Tabel 7. Berat pil kontrasepsi andalan®

Berat 20 pil andalan® (gram)	
0.0764	0.0758
0.0731	0.0763
0.0751	0.0770
0.0794	0.0762
0.0735	0.0758
0.0730	0.0769
0.0765	0.0708
0.0785	0.0776
0.0726	0.0809
0.0806	0.0727
Berat rata-rata 0.075935 gram = 75,935 mg	

Satu tablet andalan® mengandung 0.15 mg levonorgestrel setara dengan 2.5 µg/kgBB dan 0.03 mg ethinylestradiol setara dengan 0.5 µg/kgBB.

Maka dosis untuk tikus

Levonorgestrel

= 2.5 µg/kgBB x 6.2

= 15.5 µg/kgBB

Ethinylestradiol

= 0.5 µg/kgBB x 6.2

= 3.1 µg/kgBB

Dosis yang diinginkan untuk berat badan tikus 200 gram

Konversi dosis Levonorgestrel

$$\frac{15.5\ \mu g/kgBB}{1000\ gram} = \frac{X}{200\ gram}$$

X = 3.1 µg/gBB

Ethinylestradiol

$\frac{3.1\ \mu g/kgBB}{1000\ gram} = \frac{X}{200\ gram}$

X = 0.62 µg/gBB

Berat yang ditimbang

Levonorgestrel

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{3.1\ \mu g}{0.15\ mg}$ x 75.935 mg

= 1569.32 µg

Ethinylestradiol

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{0.62\ \mu g}{0.03\ mg}$ x 75.935 mg

= 1569.32 µg

Untuk tikus dengan berat badan 200gram dosis andalan

= Levonorgestrel + Ethinylestradiol

= 1569.32 µg + 1569.32 µg

= 3138.64 µg

= 3.13684 mg

= 3.14 mg

Untuk larutan stock 100 ml dengan berat badan tikus 200 gram

= $\frac{3.14\ mg}{2\ ml}$ x 100 ml

= 157 mg

= 0.157 gram

Tabel 8. Berat simvastatin 20 mg

Berat 20 tablet simvastatin 20 mg (gram)	
0.2043	0.1981
0.2042	0.2015
0.2049	0.2012
0.2054	0.2104
0.2066	0.2012
0.1951	0.2000
0.2065	0.2040
0.2058	0.2039
0.2020	0.2119
0.2022	0.2022
Berat rata-rata 0.20357 gram = 203,57 mg	

Untuk simvastatin 20 mg

20 mg/60 kgBB setara dengan 0.33 mg/kgBB maka dosis untuk tikus dengan

BB 200 gram

= dosis x 6.2

= 0.33 mg/kgBB x 6.2

= 2.1 mg/kgBB

= 2.1 mg/1000 gBB

= 0.42 mg/200 gBB

Berat simvastatin 20 mg

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{0.42\ mg}{20\ mg}$ x 203.57 mg

= 4.27497 mg

= 4.3 mg

Larutan stock untuk 25 ml pada tikus 200 gram

= $\frac{4.3\ mg}{2\ ml}$ x 25 ml

= 53.75 mg

=0.05375 gram

=0.054 gram

Konsentrasi simvastatin 20 mg sebanyak 53,75 mg yang dilarutkan dalam 25 ml NaCMC 0,05%

53,75 x 4 = 25 x 4

215 mg = 100 ml

0,215 g = 100 ml

= 0,215% (b/v)

Tabel 9. Berat fenofibrat 100 mg

Berat 20 kapsul fenofibrate 100 mg (gram)	
0.2886	0.2350
0.2377	0.2406
0.2464	0.2484
0.2418	0.2240
0.2426	0.2537
0.2416	0.2481
0.2443	0.1922
0.2442	0.2468
0.2500	0.2330
0.2330	0.2416
Berat rata-rata 0.24168 gram = 241.68 mg	

Untuk fenofibrat 100 mg

80 mg/60 kgBB setara dengan 1.33 mg/kgBB maka dosis untuk tikus dengan 200 gram

= dosis x 6.2

= 1.33 mg/kgBB x 6.2

= 8.246 mg/kgBB

= 8.246 mg/1000gBB

= 1.6492mg/200gBB

Berat fenofibrat 100 mg

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{1.6492\ mg}{100mg}$ x 241.68 mg

= 3.9857 mg

Larutan stock untuk 25 ml pada tikus 200 gram

= $\frac{3.9857\ mg}{2\ ml}$ x 25 ml

= 49.82125 mg

= 0.04982125 gram

Konsentrasi fenofibrat 100 mg sebanyak 49,82 mg yang dilarutkan dalam 25 ml NaCMC 0,05%

49,82 x 4 = 25 x 4

199,28 mg = 100 ml

0,19928 g = 100 ml

= 0,19928%(b/v)

Tabel 10. Berat rosuvastatin 10 mg

Berat 20 tablet Rosuvastatin 10 mg (gram)	
0.0822	0.0828
0.0849	0.0846
0.0842	0.0885
0.0832	0.0857
0.0853	0.0837
0.0849	0.0881
0.0867	0.0854
0.0856	0.0857
0.0863	0.0858
0.0868	0.0839
Berat rata-rata 0.085215 gram = 85.215 mg	

Untuk Rosuvastatin 10 mg

5 mg/60 kgBB setara dengan 0.083 mg/kgBB maka dosis untuk tikus dengan

200 gram

= dosis x 6.2

= 0.083 mg/kgBB x 6.2

= 0.5146 mg/kgBB

= 0.5146 mg/1000gBB

= 0.10292 mg/200gBB

Berat rosuvastatin 10 mg yang ditimbang

= $\frac{dosis\ yang\ diingikan}{berat\ etiket}$ x berat rata-rata

= $\frac{0.10292\ mg}{10mg}$ x 85.215 mg

= 0.87703 mg

Larutan stock untuk 25 ml pada tikus 200 gram

= $\frac{0.87703\ mg}{2\ ml}$ x 25 ml

= 10.962875 mg

= 0.010962675 gram

Konsentrasi rosuvastatin 10 mg sebanyak 10,96 mg yang dilarutkan dalam 25 ml NaCMC 0,05%

10,96 x 4 = 25 x 4

43,84 mg = 100 ml

0,04384 g = 100 ml

= 0,04384%(b/v)

Lampiran 4. Kode etik

KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 342/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 25 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21020116	No Sponsor Protokol	
Peneliti Utama	**Yani Pratiwi,S.Farm, Apt**	Sponsor	
Judul Peneliti	Studi Preklinik Efek Simvastatin terhadap Kadar Protein C-Reaktif dan Leptin pada Tikus Betina Dislipidemia yang Diinduksi Kontrasepsi Oral		
No Versi Protokol	**2**	Tanggal Versi	8 April 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	**Fakultas Farmasi Universitas Hasanuddin Makassar**		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **25 Mei 2021** sampai **25 Mei 2022**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 5. Surat Keterangan Selesai Penelitian

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
RUMAH SAKIT UNHAS

Jl. Perintis Kemerdekaan Km. 10 Tamalanrea, Makassar 90245

Website.www.rs.unhas.ac.id.Email.info@rs.unhas.ac.id Telp: (0411) 591331 Fax: (0411) 591332

Nomor : 108 /UN4.24.1.2/PT.01.04/2022 02 Februari 2022
Hal : **Surat Keterangan Selesai Penelitian**

Dengan ini menerangkan bahwa mahasiswa yang beridentitas :

Nama	: Yani Pratiwi
NIM	: N012191019
Institusi	: Universitas Hasanuddin Makassar
Kode Penelitian	: 210201_1

Telah menyelesaikan penelitian di Rumah Sakit Unhas.

Terhitung pada tanggal	: 30 April 2021
Dengan Sampel	: Data Primer : Elisa

Dalam rangka penyusunan Tesis yang berjudul:

"Studi Preklinik Efek Simvastatin terhadap Kadar Protein C-Reaktif dan Leptin pada Tikus Betina Dislipidemia yang Diinduksi Kontrasepsi Oral"

Demikian surat keterangan ini dibuat dan diberikan kepada yang bersangkutan untuk dipergunakan seperlunya.

Kepala Bidang Penelitian dan Inovasi

dr. Aslim Tasim,Sp.Onk.Rad, M.Kes
NIP. 198304252012121003

Lampiran 6. Dokumentasi Penelitian

1. Tahap persiapan

Gambar 6. Masa aklimatisasi Hewan uji

Gambar 7. Penyiapan bahan a. tablet andalan® b. kapsul fenofibrat 100 mg c. tablet simvastatin 20 mg d. tablet rosuvastatin 10 mg e. reagen CRP

2. Tahap penelitian pembuatan sediaan bahan uji dan pemberian oral



Gambar 8. Proses pembuatan NaCMC a. penimbangan serbuk NaCMC b. pemanasan aquadest dan NaCMC pada temperatur 80^0c

Gambar 9. Proses pembuatan suspensi Andalan® a. serbuk andalan® setelah ditimbang b. suspensi andalan®



Gambar 10. Proses pembuatan suspensi simvastatin 20 mg a. serbuk simvastatin 20 mg setelah ditimbang b. suspensi simvastatin 20 mg



Gambar 11. Proses pembuatan suspensi fenofibrat 100 mg a. serbuk fenofibrat 100 mg setelah ditimbang b. suspensi fenofibrate 100 mg



Gambar 12. a.Pembuatan suspensi rosuvastatin 10 mg b. pakan lemak kuning telur bebek

3. Tahap penelitian perlakukan pada hewan uji

Gambar 13. Pemberian sediaan secara per-oral



Gambar 14. Proses pengambilan darah a. pembiusan hewan uji menggunakan eter b. pengambilan darah melalui ekor c. pengambilan darah melalui mata



Gambar 15. Proses pengumpulan sampel

4. Tahap penelitian pengujian biomarker CRP





Gambar 16. Proses pengujian biomarker CRP

a. Sampel serum 40 µl dan antibodi CRP 10 µl ditambahkan ke dalam *wellplate*
b. Streptavidin-HRP 40 µl ditambahkan kedalam *wellplate*.
c. *wellplate* diinkubasi pada suhu 37^0C selama 1 jam
d. *Wellplate* direndam dengan 0.35 ml *wash buffer* selama 30 detik sampai 60 detik untuk setiap pembilasan dilakukan sebanyak 5 kali.
e. Larutan stop 50 µl ditambahkan pada *wellplate*
f. pembacaan biomarker CRP menggunakan Kit ELISA READER dengan Panjang gelombang 450 nm selama 10 menit

5. Tahap penelitian pengujian biomarker LDH



Gambar 17. Proses pengujian biomarker LDH

a. Pembuatan reagen kerja (*working reagen*)

b. Penambahan reagen kerja 1000 µl kedalam tabung yang berisi sampel 10 µl

c. Inkubasai sampel pada suhu 37°C selama satu menit

d. Pembacaan absorbansi setelah inkubasi

Lampiran 7. Analisis statistik

Uji Paired T-Test CRP Kelompok 3-6 untuk hari 0 dan 30

Kelompok 3

Tests of Normality

kelompokPerlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	Df	Sig.	Statistic	df	Sig.
A_PK_Na_CRPH_0	Andalan+PakanLemak+Nacmc	,213	5	,200*	,963	5	,827
A_PK_Na_CRPH_30	Andalan+PakanLemak+Nacmc	,163	5	,200*	,981	5	,941

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	A_PK_Na_CRPH_0 - A_PK_Na_CRPH_30	-,34398	,39097	,17485	-,82943	,14147	-1,967	4	,121

Kelompok 4

Tests of Normality

KelompokPerlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
A_PK_S_CRPH_0	andalan+pakanlemak+Simvastatin	,192	5	,200*	,980	5	,934
A_PK_S_CRPH_30	andalan+pakanlemak+Simvastatin	,229	5	,200*	,922	5	,540

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	A_PK_S_CRPH_0 - A_PK_S_CRPH_30	-,26674	,17455	,07806	-,48348	-,05000	-3,417	4	,027

Kelompok 5

Tests of Normality

KelompokPerlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
A_PK_R_CRPH_0	Andalan+PakanLemak+Rosuvastatin	,313	5	,123	,833	5	,147
A_PK_R_CRPH_30	Andalan+PakanLemak+Rosuvastatin	,231	5	,200*	,961	5	,813

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	A_PK_R_CRPH_0 - A_PK_R_CRPH_30	-,40302	,18273	,08172	-,62991	-,17613	-4,932	4	,008

Kelompok 6

Tests of Normality

KelompokPerlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
A_PK_F_CRPH_0	Andalan+PakanLemak+Fenofibrat	,246	4	.	,915	4	,510
A_PK_F_CRPH_30	Andalan+PakanLemak+Fenofibrat	,284	4	.	,877	4	,328

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	A_PK_F_CRPH_0 - A_PK_F_CRPH_30	-,28830	,24025	,12012	-,67059	,09399	-2,400	3	,096

UJI ONE WAY ANOVA Kelompok 3 sampai 6 data hari ke 0 dan 30

Tests of Normality

KelompokPerlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Hari_0	Andalan+PakanLemak+NaCMC	.213	5	.200*	.963	5	.827
	Andalan+PakanLemak+Simvastatin	.192	5	.200*	.980	5	.934
	Andalan+PakanLemak+Rosuvastatin	.313	5	.123	.833	5	.147
	Andalan+PakanLemak+Fenofibrat	.246	4	.	.915	4	.510
Hari_30	Andalan+PakanLemak+NaCMC	.163	5	.200*	.981	5	.941
	Andalan+PakanLemak+Simvastatin	.229	5	.200*	.922	5	.540
	Andalan+PakanLemak+Rosuvastatin	.231	5	.200*	.961	5	.813
	Andalan+PakanLemak+Fenofibrat	.284	4	.	.877	4	.328

Descriptives

		N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean Lower Bound	Upper Bound	Minimum	Maximum
Hari_0	Andalan+Pakan Lemak+NaCMC	5	2.1985	.10270	.04593	2.0710	2.3260	2.04	2.32
	Andalan+Pakan Lemak+Simvastatin	5	2.2343	.04935	.02207	2.1730	2.2956	2.18	2.30
	Andalan+Pakan Lemak+Rosuvastatin	5	2.2244	.09524	.04259	2.1061	2.3427	2.15	2.37
	Andalan+Pakan Lemak+Fenofibrat	4	2.1932	.08890	.04445	2.0517	2.3347	2.10	2.29
	Total	19	2.2136	.08078	.01853	2.1747	2.2525	2.04	2.37
Hari_30	Andalan+Pakan Lemak+NaCMC	5	2.5425	.41253	.18449	2.0303	3.0547	2.06	3.15
	Andalan+Pakan Lemak+Simvastatin	5	2.5010	.17845	.07981	2.2794	2.7226	2.23	2.67
	Andalan+Pakan Lemak+Rosuvastatin	5	2.6274	.14699	.06574	2.4449	2.8099	2.45	2.85
	Andalan+Pakan Lemak+Fenofibrat	4	2.4815	.20832	.10416	2.1500	2.8130	2.30	2.73
	Total	19	2.5411	.24543	.05631	2.4228	2.6594	2.06	3.15

Test of Homogeneity of Variances

	Levene Statistic	df1	df2	Sig.
Hari_0	.879	3	15	.474
Hari_30	1.858	3	15	.180

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
Hari_0	Between Groups	.006	3	.002	.247	.862
	Within Groups	.112	15	.007		
	Total	.117	18			
Hari_30	Between Groups	.060	3	.020	.290	.832
	Within Groups	1.025	15	.068		
	Total	1.084	18			

Robust Tests of Equality of Means

		Statistic[a]	df1	df2	Sig.
Hari_0	Welch	.282	3	7.590	.837
Hari_30	Welch	.618	3	7.811	.623

a. Asymptotically F distributed.

Multiple Comparisons

Dependent Variable		(I) KelompokPerlakuan	(J) KelompokPerlakuan	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval Lower Bound	95% Confidence Interval Upper Bound
Hari_0	Tukey HSD	Andalan+Pakan Lemak+NaCMC	Andalan+Pakan Lemak+Simvastatin	-.03578	.05463	.912	-.1932	.1217
			Andalan+Pakan Lemak+Rosuvastatin	-.02590	.05463	.964	-.1834	.1316
			Andalan+Pakan Lemak+Fenofibrat	.00530	.05794	1.000	-.1617	.1723
		Andalan+Pakan Lemak+Simvastatin	Andalan+Pakan Lemak+NaCMC	.03578	.05463	.912	-.1217	.1932
			Andalan+Pakan Lemak+Rosuvastatin	.00988	.05463	.998	-.1476	.1673

		Andalan+Pakan Lemak+Fenofibrat	.04108	.05794	.892	-.1259	.2081
	Andalan+Pakan Lemak+Rosuvastatin	Andalan+Pakan Lemak+NaCMC	.02590	.05463	.964	-.1316	.1834
		Andalan+Pakan Lemak+Simvastatin	-.00988	.05463	.998	-.1673	.1476
		Andalan+Pakan Lemak+Fenofibrat	.03120	.05794	.948	-.1358	.1982
	Andalan+Pakan Lemak+Fenofibrat	Andalan+Pakan Lemak+NaCMC	-.00530	.05794	1.000	-.1723	.1617
		Andalan+Pakan Lemak+Simvastatin	-.04108	.05794	.892	-.2081	.1259
		Andalan+Pakan Lemak+Rosuvastatin	-.03120	.05794	.948	-.1982	.1358
Games-Howell	Andalan+Pakan Lemak+NaCMC	Andalan+Pakan Lemak+Simvastatin	-.03578	.05095	.893	-.2146	.1430
		Andalan+Pakan Lemak+Rosuvastatin	-.02590	.06264	.975	-.2267	.1749
		Andalan+Pakan Lemak+Fenofibrat	.00530	.06391	1.000	-.2070	.2176
	Andalan+Pakan Lemak+Simvastatin	Andalan+Pakan Lemak+NaCMC	.03578	.05095	.893	-.1430	.2146
		Andalan+Pakan Lemak+Rosuvastatin	.00988	.04797	.997	-.1562	.1759
		Andalan+Pakan Lemak+Fenofibrat	.04108	.04963	.840	-.1509	.2331

		Andalan+Pakan Lemak+Rosuvastatin	Andalan+Pakan Lemak+NaCMC	.02590	.06264	.975	-.1749	.2267
			Andalan+Pakan Lemak+Simvastatin	-.00988	.04797	.997	-.1759	.1562
			Andalan+Pakan Lemak+Fenofibrat	.03120	.06156	.955	-.1745	.2369
		Andalan+Pakan Lemak+Fenofibrat	Andalan+Pakan Lemak+NaCMC	-.00530	.06391	1.000	-.2176	.2070
			Andalan+Pakan Lemak+Simvastatin	-.04108	.04963	.840	-.2331	.1509
			Andalan+Pakan Lemak+Rosuvastatin	-.03120	.06156	.955	-.2369	.1745
Hari_30	Tukey HSD	Andalan+Pakan Lemak+NaCMC	Andalan+Pakan Lemak+Simvastatin	.04146	.16531	.994	-.4350	.5179
			Andalan+Pakan Lemak+Rosuvastatin	-.08494	.16531	.954	-.5614	.3915
			Andalan+Pakan Lemak+Fenofibrat	.06098	.17533	.985	-.4444	.5663
		Andalan+Pakan Lemak+Simvastatin	Andalan+Pakan Lemak+NaCMC	-.04146	.16531	.994	-.5179	.4350
			Andalan+Pakan Lemak+Rosuvastatin	-.12640	.16531	.869	-.6028	.3500
			Andalan+Pakan Lemak+Fenofibrat	.01952	.17533	.999	-.4858	.5249
			Andalan+Pakan Lemak+NaCMC	.08494	.16531	.954	-.3915	.5614

	Andalan+Pakan Lemak+Rosuvastatin	Andalan+Pakan Lemak+Simvastatin	.12640	.16531	.869	-.3500	.6028
		Andalan+Pakan Lemak+Fenofibrat	.14592	.17533	.838	-.3594	.6513
	Andalan+Pakan Lemak+Fenofibrat	Andalan+Pakan Lemak+NaCMC	-.06098	.17533	.985	-.5663	.4444
		Andalan+Pakan Lemak+Simvastatin	-.01952	.17533	.999	-.5249	.4858
		Andalan+Pakan Lemak+Rosuvastatin	-.14592	.17533	.838	-.6513	.3594
Games-Howell	Andalan+Pakan Lemak+NaCMC	Andalan+Pakan Lemak+Simvastatin	.04146	.20101	.997	-.6772	.7601
		Andalan+Pakan Lemak+Rosuvastatin	-.08494	.19585	.970	-.8076	.6378
		Andalan+Pakan Lemak+Fenofibrat	.06098	.21186	.991	-.6677	.7896
	Andalan+Pakan Lemak+Simvastatin	Andalan+Pakan Lemak+NaCMC	-.04146	.20101	.997	-.7601	.6772
		Andalan+Pakan Lemak+Rosuvastatin	-.12640	.10339	.632	-.4603	.2075
		Andalan+Pakan Lemak+Fenofibrat	.01952	.13122	.999	-.4346	.4737
	Andalan+Pakan Lemak+Rosuvastatin	Andalan+Pakan Lemak+NaCMC	.08494	.19585	.970	-.6378	.8076
		Andalan+Pakan Lemak+Simvastatin	.12640	.10339	.632	-.2075	.4603

		Andalan+Pakan Lemak+Fenofibrat	.14592	.12317	.660	-.3005	.5924
	Andalan+Pakan Lemak+Fenofibrat	Andalan+Pakan Lemak+NaCMC	-.06098	.21186	.991	-.7896	.6677
		Andalan+Pakan Lemak+Simvastatin	-.01952	.13122	.999	-.4737	.4346
		Andalan+Pakan Lemak+Rosuvastatin	-.14592	.12317	.660	-.5924	.3005

Homogeneous Subsets

Hari_0

	KelompokPerlakuan	N	Subset for alpha = 0.05 1
Tukey HSD[a,b]	Andalan+PakanLemak+Fenofibrat	4	2.1932
	Andalan+PakanLemak+NaCMC	5	2.1985
	Andalan+PakanLemak+Rosuvastatin	5	2.2244
	Andalan+PakanLemak+Simvastatin	5	2.2343
	Sig.		.884

Hari_30

	KelompokPerlakuan	N	Subset for alpha = 0.05 1
Tukey HSD[a,b]	Andalan+PakanLemak+Fenofibrat	4	2.4815
	Andalan+PakanLemak+Simvastatin	5	2.5010
	Andalan+PakanLemak+NaCMC	5	2.5425
	Andalan+PakanLemak+Rosuvastatin	5	2.6274
	Sig.		.827

Uji Paired T-Test Kelompok 3-6 untuk hari 30 dan 60

Kelompok 3

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	KelompokPerlakuan	Statistic	df	Sig.	Statistic	df	Sig.
Hari_30	A+PK+Na	,163	5	,200*	,981	5	,941
Hari_60	A+PK+Na	,335	5	,068	,757	5	,034

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
					95% Confidence Interval of the Difference				
		Mean	Std. Deviation	Std. Error Mean	Lower	Upper			
Pair 1	Hari_30 - Hari_60	,34838	,72083	,32236	-,54665	1,24341	1,081	4	,341

Kelompok 4

Tests of Normality

	KelompokPerlakuan	Kolmogorov-Smirnov[a] Statistic	df	Sig.	Shapiro-Wilk Statistic	df	Sig.
Hari30	A+PK+S	,229	5	,200*	,922	5	,540
Hari60	A+PK+S	,231	5	,200*	,855	5	,212

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Hari30 - Hari60	,36176	,30184	,13499	-,01303	,73655	2,680	4	,055

Kelompok 5

Tests of Normality

	KelompokPerlakuan	Kolmogorov-Smirnov[a] Statistic	df	Sig.	Shapiro-Wilk Statistic	df	Sig.
Hari30	A+PK+R	,231	5	,200*	,961	5	,813
Hari60	A+PK+R	,220	5	,200*	,922	5	,544

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Hari30 - Hari60	,15856	,38306	,17131	-,31707	,63419	,926	4	,407

Kelompok 6

Tests of Normality

	KelompokPerlakuan	Kolmogorov-Smirnov[a] Statistic	df	Sig.	Shapiro-Wilk Statistic	df	Sig.
Hari30	A+PK+F	,284	4	.	,877	4	,328
Hari60	A+PK+F	,276	4	.	,864	4	,274

a. Lilliefors Significance Correction

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	Hari30 - Hari60	-,26643	,50680	,25340	-1,07286	,54001	-1,051	3	,370

Uji One Way Anova % kenaikkan hari 30 dan 60 kelompok 3 sampai 6

Tests of Normality

	KelompokPerlakuan	Kolmogorov-Smirnov[a] Statistic	df	Sig.	Shapiro-Wilk Statistic	df	Sig.
Hari30_60	A+PK+Na	.305	5	.145	.871	5	.270
	A+PK+S	.135	5	.200*	.986	5	.963
	A+PK+R	.197	5	.200*	.962	5	.822
	A+PK+F	.178	4	.	.994	4	.976

Descriptives

Hari30_60

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean Lower Bound	Upper Bound	Minimum	Maximum
A+PK+Na	5	-10.4600	27.54901	12.32029	-44.6666	23.7466	-37.50	25.70
A+PK+S	5	-13.8800	11.46547	5.12751	-28.1163	.3563	-27.90	1.20
A+PK+R	5	-5.6000	14.71343	6.58005	-23.8691	12.6691	-23.90	12.70
A+PK+F	4	11.6921	20.64634	10.32317	-21.1608	44.5450	-14.28	35.16
Total	19	-5.4175	20.22471	4.63987	-15.1655	4.3305	-37.50	35.16

Test of Homogeneity of Variances

Hari30_60

Levene Statistic	df1	df2	Sig.
2.977	3	15	.065

ANOVA

Hari30_60

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	1656.323	3	552.108	1.451	.268
Within Groups	5706.375	15	380.425		
Total	7362.698	18			

Robust Tests of Equality of Means

Hari30_60

	Statistic[a]	df1	df2	Sig.
Welch	1.455	3	7.656	.301

Multiple Comparisons

Dependent Variable: Hari30_60

	(I) Kelompok Perlakuan	(J) Kelompok Perlakuan	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval Lower Bound	95% Confidence Interval Upper Bound
Tukey HSD	A+PK+Na	A+PK+S	3.42000	12.33572	.992	-32.1334	38.9734
		A+PK+R	-4.86000	12.33572	.978	-40.4134	30.6934
		A+PK+F	-22.15210	13.08401	.361	-59.8621	15.5580
	A+PK+S	A+PK+Na	-3.42000	12.33572	.992	-38.9734	32.1334
		A+PK+R	-8.28000	12.33572	.906	-43.8334	27.2734
		A+PK+F	-25.57210	13.08401	.248	-63.2821	12.1380
	A+PK+R	A+PK+Na	4.86000	12.33572	.978	-30.6934	40.4134
		A+PK+S	8.28000	12.33572	.906	-27.2734	43.8334
		A+PK+F	-17.29210	13.08401	.564	-55.0021	20.4180
	A+PK+F	A+PK+Na	22.15210	13.08401	.361	-15.5580	59.8621
		A+PK+S	25.57210	13.08401	.248	-12.1380	63.2821
		A+PK+R	17.29210	13.08401	.564	-20.4180	55.0021
Games-Howell	A+PK+Na	A+PK+S	3.42000	13.34470	.993	-44.6096	51.4496
		A+PK+R	-4.86000	13.96734	.984	-52.9364	43.2164
		A+PK+F	-22.15210	16.07350	.549	-75.3730	31.0688
	A+PK+S	A+PK+Na	-3.42000	13.34470	.993	-51.4496	44.6096
		A+PK+R	-8.28000	8.34197	.758	-35.3649	18.8049
		A+PK+F	-25.57210	11.52646	.249	-70.1631	19.0189
	A+PK+R	A+PK+Na	4.86000	13.96734	.984	-43.2164	52.9364
		A+PK+S	8.28000	8.34197	.758	-18.8049	35.3649
		A+PK+F	-17.29210	12.24193	.541	-61.5510	26.9668
	A+PK+F	A+PK+Na	22.15210	16.07350	.549	-31.0688	75.3730
		A+PK+S	25.57210	11.52646	.249	-19.0189	70.1631
		A+PK+R	17.29210	12.24193	.541	-26.9668	61.5510

Homogeneous Subsets

Hari30_60

	KelompokPerlakuan	N	Subset for alpha = 0.05 1
Tukey HSD[a,b]	A+PK+S	5	-13.8800
	A+PK+Na	5	-10.4600
	A+PK+R	5	-5.6000
	A+PK+F	4	11.6921
	Sig.		.227

Uji Paired T-Test Hari 0 ke 60 kelompok 3 sampai 6 Kelompok 3

Tests of Normality

	Kelompok_ Perlakuan	Kolmogorov-Smirnov[a] Statistic	df	Sig.	Shapiro-Wilk Statistic	df	Sig.
CRP_APKNa_H0	A+PK+NaCMC	.213	5	.200*	.963	5	.827
CRP_APKNa_H60	A+PK+NaCMC	.335	5	.068	.757	5	.034

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	CRP_APKNa_H0 - CRP_APKNa_H60	.00440	.44857	.20061	-.55258	.56138	.022	4	.984

Kelompok 4

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
CRP_APKS_H0	A+PK+S	.192	5	.200*	.980	5	.934
CRP_APKS_H60	A+PK+S	.231	5	.200*	.855	5	.212

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	CRP_APKS_H0 - CRP_APKS_H60	.09502	.14544	.06504	-.08556	.27560	1.461	4	.218

Kelompok 5

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
CRP_APKR_H0	A+PK+R	.313	5	.123	.833	5	.147
CRP_APKR_H60	A+PK+R	.220	5	.200*	.922	5	.544

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	CRP_APKR_H0 – CRP_APKR_H60	-.24446	.31127	.13920	-.63095	.14203	-1.756	4	.154

Kelompok 6

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
CRP_APKF_H0	A+PK+F	.246	4	.	.915	4	.510
CRP_APKF_H60	A+PK+F	.276	4	.	.864	4	.274

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	CRP_APKF_H0 - CRP_APKF_H60	-.55473	.40910	.20455	-1.20570	.09625	-2.712	3	.073

Uji Paired T-Test LDH Kelompok 3 samapi 6 untuk hari 0 dan 30

Kelompok 3

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKNa_H0	A+PK+NaCMC	.199	5	.200*	.983	5	.950
LDH_APKNa_H30	A+PK+NaCMC	.252	5	.200*	.809	5	.095

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
					95% Confidence Interval of the Difference				
		Mean	Std. Deviation	Std. Error Mean	Lower	Upper			
Pair 1	LDH_APKNa_H0 - LDH_APKNa_H30	-267.82000	280.06392	125.24839	-615.56528	79.92528	-2.138	4	.099

Kelompok 4

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKS_H0	A+PK+S	.283	4	.	.870	4	.298
LDH_APKS_H30	A+PK+S	.400	4	.	.702	4	.012

a. Lilliefors Significance Correction

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKS_H0 - LDH_APKS_H30	-501.95000	235.91262	117.95631	-877.33962	-126.56038	-4.255	3	.024

Kelompok 5

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKR_H0	A+PK+R	.189	5	.200*	.961	5	.818
LDH_APKR_H30	A+PK+R	.324	5	.094	.842	5	.171

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKR_H0 - LDH_APKR_H30	-448.46000	143.00695	63.95465	-626.02658	-270.89342	-7.012	4	.002

Kelompok 6

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKF_H0	A+PK+F	.202	5	.200*	.933	5	.614
LDH_APKF_H30	A+PK+F	.293	5	.185	.862	5	.234

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	LDH_APKF_H0 - LDH_APKF_H30	-555.68000	350.64900	156.81500	-991.06824	-120.29176	-3.544	4	.024

Uji One Way ANOVA hari 0 ke 30 kelompok 3 sampai 6

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_H0	A+PK+NaCMC	.199	5	.200*	.983	5	.950
	A+PK+S	.283	4	.	.870	4	.298
	A+PK+R	.189	5	.200*	.961	5	.818
	A+PK+F	.202	5	.200*	.933	5	.614
LDH_H30	A+PK+NaCMC	.252	5	.200*	.809	5	.095
	A+PK+S	.400	4	.	.702	4	.012
	A+PK+R	.324	5	.094	.842	5	.171
	A+PK+F	.293	5	.185	.862	5	.234

Descriptives

		N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean Lower Bound	Upper Bound	Minimum	Maximum
LDH_H0	A+PK+NaCMC	5	640.7000	181.76134	81.28614	415.0135	866.3865	399.50	896.80
	A+PK+S	4	723.3000	101.01211	50.50606	562.5672	884.0328	609.70	814.40
	A+PK+R	5	754.6600	241.23229	107.88236	455.1305	1054.1894	473.00	1061.00
	A+PK+F	5	601.7200	282.03635	126.13049	251.5256	951.9144	278.30	941.50
	Total	19	677.8211	209.14513	47.98118	577.0163	778.6258	278.30	1061.00
LDH_H30	A+PK+NaCMC	5	908.5200	308.72546	138.06622	525.1867	1291.8533	569.20	1193.00
	A+PK+S	4	1225.2500	289.50691	144.75345	764.5799	1685.9201	1057.00	1658.00
	A+PK+R	5	1203.1200	270.18100	120.82862	867.6460	1538.5940	947.60	1660.00
	A+PK+F	5	1157.4000	150.64130	67.36884	970.3541	1344.4459	1010.00	1409.00
	Total	19	1118.2211	271.29916	62.24030	987.4590	1248.9831	569.20	1660.00

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
LDH_H0	Between Groups	73641.172	3	24547.057	.516	.678
	Within Groups	713709.160	15	47580.611		
	Total	787350.332	18			
LDH_H30	Between Groups	309407.546	3	103135.849	1.523	.249
	Within Groups	1015450.686	15	67696.712		
	Total	1324858.232	18			

Robust Tests of Equality of Means

		Statistic[a]	df1	df2	Sig.
LDH_H0	Welch	.460	3	8.147	.718
LDH_H30	Welch	.991	3	7.571	.447

Multiple Comparisons

Dependent Variable		(I) Kelompok_ Perlakuan	(J) Kelompok_ Perlakuan	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval Lower Bound	Upper Bound
LDH_H0	Tukey HSD		A+PK+S	-82.60000	146.32592	.941	-504.3331	339.1331

		A+PK+NaCMC	A+PK+R	-113.96000	137.95740	.841	-511.5737	283.6537
			A+PK+F	38.98000	137.95740	.992	-358.6337	436.5937
		A+PK+S	A+PK+NaCMC	82.60000	146.32592	.941	-339.1331	504.3331
			A+PK+R	-31.36000	146.32592	.996	-453.0931	390.3731
			A+PK+F	121.58000	146.32592	.839	-300.1531	543.3131
		A+PK+R	A+PK+NaCMC	113.96000	137.95740	.841	-283.6537	511.5737
			A+PK+S	31.36000	146.32592	.996	-390.3731	453.0931
			A+PK+F	152.94000	137.95740	.690	-244.6737	550.5537
		A+PK+F	A+PK+NaCMC	-38.98000	137.95740	.992	-436.5937	358.6337
			A+PK+S	-121.58000	146.32592	.839	-543.3131	300.1531
			A+PK+R	-152.94000	137.95740	.690	-550.5537	244.6737
	Games-Howell	A+PK+NaCMC	A+PK+S	-82.60000	95.69900	.823	-407.2699	242.0699
			A+PK+R	-113.96000	135.07791	.833	-554.1958	326.2758
			A+PK+F	38.98000	150.05445	.993	-460.9577	538.9177
		A+PK+S	A+PK+NaCMC	82.60000	95.69900	.823	-242.0699	407.2699
			A+PK+R	-31.36000	119.11954	.993	-453.4799	390.7599
			A+PK+F	121.58000	135.86671	.809	-372.1170	615.2770
		A+PK+R	A+PK+NaCMC	113.96000	135.07791	.833	-326.2758	554.1958
			A+PK+S	31.36000	119.11954	.993	-390.7599	453.4799
			A+PK+F	152.94000	165.97441	.795	-381.5221	687.4021
		A+PK+F	A+PK+NaCMC	-38.98000	150.05445	.993	-538.9177	460.9577
			A+PK+S	-121.58000	135.86671	.809	-615.2770	372.1170
			A+PK+R	-152.94000	165.97441	.795	-687.4021	381.5221
LDH_H30	Tukey HSD	A+PK+NaCMC	A+PK+S	-316.73000	174.53802	.305	-819.7745	186.3145
			A+PK+R	-294.60000	164.55602	.316	-768.8749	179.6749
			A+PK+F	-248.88000	164.55602	.455	-723.1549	225.3949
		A+PK+S	A+PK+NaCMC	316.73000	174.53802	.305	-186.3145	819.7745
			A+PK+R	22.13000	174.53802	.999	-480.9145	525.1745

			A+PK+F	67.85000	174.53802	.979	-435.1945	570.8945
		A+PK+R	A+PK+NaCMC	294.60000	164.55602	.316	-179.6749	768.8749
			A+PK+S	-22.13000	174.53802	.999	-525.1745	480.9145
			A+PK+F	45.72000	164.55602	.992	-428.5549	519.9949
		A+PK+F	A+PK+NaCMC	248.88000	164.55602	.455	-225.3949	723.1549
			A+PK+S	-67.85000	174.53802	.979	-570.8945	435.1945
			A+PK+R	-45.72000	164.55602	.992	-519.9949	428.5549
	Games-Howell	A+PK+NaCMC	A+PK+S	-316.73000	200.03961	.446	-985.4482	351.9882
			A+PK+R	-294.60000	183.47162	.428	-884.5264	295.3264
			A+PK+F	-248.88000	153.62566	.437	-786.4443	288.6843
		A+PK+S	A+PK+NaCMC	316.73000	200.03961	.446	-351.9882	985.4482
			A+PK+R	22.13000	188.55534	.999	-619.9171	664.1771
			A+PK+F	67.85000	159.66253	.971	-560.7159	696.4159
		A+PK+R	A+PK+NaCMC	294.60000	183.47162	.428	-295.3264	884.5264
			A+PK+S	-22.13000	188.55534	.999	-664.1771	619.9171
			A+PK+F	45.72000	138.34057	.986	-426.7714	518.2114
		A+PK+F	A+PK+NaCMC	248.88000	153.62566	.437	-288.6843	786.4443
			A+PK+S	-67.85000	159.66253	.971	-696.4159	560.7159
			A+PK+R	-45.72000	138.34057	.986	-518.2114	426.7714

Kelompok_Perlakuan		N	Subset for alpha = 0.05
			1
Tukey HSD[a,b]	A+PK+F	5	601.7200
	A+PK+NaCMC	5	640.7000
	A+PK+S	4	723.3000
	A+PK+R	5	754.6600
	Sig.		.709

LDH_H30

Kelompok_Perlakuan		N	Subset for alpha = 0.05 1
Tukey HSD[a,b]	A+PK+NaCMC	5	908.5200
	A+PK+F	5	1157.4000
	A+PK+R	5	1203.1200
	A+PK+S	4	1225.2500
	Sig.		.283

Uji Paired T-Test kelompok 3 sampai 6 hari ke 30 dan 60
Kelompok 3

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKNa_H30	A+PK+NaCMC	.252	5	.200*	.809	5	.095
LDH_APKNa_H60	A+PK+NaCMC	.196	5	.200*	.942	5	.682

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKNa_H30 - LDH_APKNa_H60	-43.90000	345.23317	154.39297	-472.56360	384.76360	-.284	4	.790

Kelompok 4

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKS_H30	A+PK+S	.400	4	.	.702	4	.012

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKS_H30 - LDH_APKS_H60	316.05000	311.34909	155.67455	-179.37588	811.47588	2.030	3	.135

LDH_APKS_H60	A+PK+S	.240	4	.	.969	4	.838

Kelompok 5

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKR_H30	A+PK+R	.324	5	.094	.842	5	.171
LDH_APKR_H60	A+PK+R	.278	5	.200*	.877	5	.295

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKR_H30 - LDH_APKR_H60	325.54000	835.93728	373.84252	-712.41323	1363.49323	.871	4	.433

Kelompok 6

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	Df	Sig.
LDH_APKF_H30	A+PK+F	.293	5	.185	.862	5	.234
LDH_APKF_H60	A+PK+F	.270	5	.200*	.854	5	.207

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKF_H30 - LDH_APKF_H60	322.94000	338.94343	151.58011	-97.91385	743.79385	2.130	4	.100

Uji One Way ANOVA % Kenaikan hari 30 ke 60 kelompok 3 sampai 6

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_H30_H60	A+PK+NaCMC	.190	5	.200*	.937	5	.643
	A+PK+S	.178	5	.200*	.957	5	.789
	A+PK+R	.256	5	.200*	.870	5	.268
	A+PK+F	.333	5	.072	.742	5	.025

Descriptives

LDH_H30_H60

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean Lower Bound	Upper Bound	Minimum	Maximum
A+PK+NaCMC	5	15.5600	50.09679	22.40396	-46.6434	77.7634	-35.50	94.10
A+PK+S	5	-34.4600	29.67563	13.27135	-71.3072	2.3872	-79.50	-2.70
A+PK+R	5	-18.4600	70.35878	31.46540	-105.8220	68.9020	-80.40	96.80
A+PK+F	5	-26.3000	26.31302	11.76754	-58.9719	6.3719	-56.10	-5.20
Total	20	-15.9150	47.78066	10.68408	-38.2770	6.4470	-80.40	96.80

Test of Homogeneity of Variances

LDH_H30_H60

Levene Statistic	df1	df2	Sig.
1.529	3	16	.245

ANOVA

LDH_H30_H60

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	7244.590	3	2414.863	1.069	.390
Within Groups	36132.256	16	2258.266		
Total	43376.845	19			

Multiple Comparisons

Dependent Variable: LDH_H30_H60

	(I) Kelompok_ Perlakuan	(J) Kelompok_Perlakuan	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
Tukey HSD	A+PK+NaCMC	A+PK+S	50.02000	30.05506	.373	-35.9681	136.0081
		A+PK+R	34.02000	30.05506	.676	-51.9681	120.0081
		A+PK+F	41.86000	30.05506	.521	-44.1281	127.8481
	A+PK+S	A+PK+NaCMC	-50.02000	30.05506	.373	-136.0081	35.9681
		A+PK+R	-16.00000	30.05506	.950	-101.9881	69.9881
		A+PK+F	-8.16000	30.05506	.993	-94.1481	77.8281
	A+PK+R	A+PK+NaCMC	-34.02000	30.05506	.676	-120.0081	51.9681
		A+PK+S	16.00000	30.05506	.950	-69.9881	101.9881
		A+PK+F	7.84000	30.05506	.994	-78.1481	93.8281
	A+PK+F	A+PK+NaCMC	-41.86000	30.05506	.521	-127.8481	44.1281
		A+PK+S	8.16000	30.05506	.993	-77.8281	94.1481
		A+PK+R	-7.84000	30.05506	.994	-93.8281	78.1481
Games-Howell	A+PK+NaCMC	A+PK+S	50.02000	26.03970	.306	-37.9696	138.0096
		A+PK+R	34.02000	38.62653	.815	-92.7782	160.8182
		A+PK+F	41.86000	25.30637	.419	-45.5108	129.2308
	A+PK+S	A+PK+NaCMC	-50.02000	26.03970	.306	-138.0096	37.9696
		A+PK+R	-16.00000	34.14967	.963	-138.6297	106.6297

		A+PK+F	-8.16000	17.73707	.966	-65.1482	48.8282
	A+PK+R	A+PK+NaCMC	-34.02000	38.62653	.815	-160.8182	92.7782
		A+PK+S	16.00000	34.14967	.963	-106.6297	138.6297
		A+PK+F	7.84000	33.59385	.995	-115.2056	130.8856
	A+PK+F	A+PK+NaCMC	-41.86000	25.30637	.419	-129.2308	45.5108
		A+PK+S	8.16000	17.73707	.966	-48.8282	65.1482
		A+PK+R	-7.84000	33.59385	.995	-130.8856	115.2056

LDH_H30_H60

Kelompok_Perlakuan		N	Subset for alpha = 0.05
			1
Tukey HSD[a]	A+PK+S	5	-34.4600
	A+PK+F	5	-26.3000
	A+PK+R	5	-18.4600
	A+PK+NaCMC	5	15.5600
	Sig.		.373

Uji Paired T-Test Kelompok 3 sampai 6 hari 0 ke 60

Kelompok 3

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKNa_H0	A+PK+NaCMC	.199	5	.200*	.983	5	.950
LDH_APKNa_H60	A+PK+NaCMC	.196	5	.200*	.942	5	.682

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKNa_H0 - LDH_APKNa_H60	-311.72000	394.07127	176.23403	-801.02410	177.58410	-1.769	4	.152

Kelompok 4

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKS_H0	A+PK+S	.283	4	.	.870	4	.298
LDH_APKS_H60	A+PK+S	.240	4	.	.969	4	.838

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKS_H0 - LDH_APKS_H60	-185.90000	166.08094	83.04047	-450.17184	78.37184	-2.239	3	.111

Kelompok 5

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKR_H0	A+PK+R	.189	5	.200*	.961	5	.818
LDH_APKR_H60	A+PK+R	.278	5	.200*	.877	5	.295

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKR_H0 - LDH_APKR_H60	-122.92000	827.15719	369.91594	-1149.97130	904.13130	-.332	4	.756

Kelompok 6

Tests of Normality

Kelompok_Perlakuan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
LDH_APKF_H0	A+PK+F	.202	5	.200*	.933	5	.614
LDH_APKF_H60	A+PK+F	.270	5	.200*	.854	5	.207

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower	Upper			
Pair 1	LDH_APKF_H0 - LDH_APKF_H60	-232.74000	447.59695	200.17144	-788.50502	323.02502	-1.163	4	.310